Skip to content

Virtual Reality Aggression Prevention Training (VRAPT) - Arousal Module: a Pilot Feasibility Study in Forensic Psychiatric Inpatients.

Virtual Reality Aggression Prevention Training (VRAPT) - Arousal Module: a Pilot Feasibility Study in Forensic Psychiatric Inpatients. - VRAPT Arousal Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57299
Enrollment
10
Registered
2025-02-06
Start date
2025-03-01
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggression Regulation disorder - Aggression

Interventions

This research has initiated the development of a new, modular version of VRAPT. Within the scope of the present study, the feasibility of the first module - VRAPT Arousal - is studied. All patients

Sponsors

Universiteit van Tilburg
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years of age and older. - Forensic psychiatric inpatient in FPC *De Kijvelanden'. - The presence of aggression regulation problems. - Convicted to TBS for a violent crime. - Referred to aggression prevention training by their head of treatment. - Understanding of Dutch language.

Exclusion criteria

Exclusion criteria: - Active use of narcotics. - Experiencing an active psychotic episode. - (history) of epilepsy

Design outcomes

Primary

MeasureTime frame
The primary study parameter is the experience with the VRAPT-Arousal module. This study parameter is measured using both qualitative and quantitative measures. Qualitative data will be collected through semi-structured interviews, while the quantitative measure is composed of the Session Rating Scale (SRS; Duncan et al., 2003).

Secondary

MeasureTime frame
The secondary study parameters entail biomarker data from the wearable that patients wear during sessions, combined with the data from the Anger Bodily Sensations Questionnaire (ABSQ; Zwets et al., 2014) and the Multidimensional Assessment of Interoceptive Awareness (MAIA; Mehling et al., 2018). This data will be used to investigate the validity of using the Nowatch wearable as a measurement device for arousal and its corresponding biomarkers (skin sympathetic nerve activity and heart rhythm).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026